Detalhe da pesquisa
1.
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.
Am J Hematol
; 99(2): 254-262, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38108611
2.
Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML.
Int J Mol Sci
; 24(4)2023 Feb 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36834477
3.
The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia.
Thromb Res
; 236: 30-36, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38387301
4.
Therapy-related Myeloid Neoplasms: Considerations for Patients' Clinical Evaluation.
Mediterr J Hematol Infect Dis
; 15(1): e2023051, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37705524
5.
Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience.
Cancers (Basel)
; 14(22)2022 Nov 17.
Artigo
Inglês
| MEDLINE | ID: mdl-36428732
6.
In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia.
J Clin Med
; 11(7)2022 Mar 23.
Artigo
Inglês
| MEDLINE | ID: mdl-35407383
7.
Occult central nervous system involvement guides therapeutic choices in blastic plasmacytoid dendritic cell neoplasms.
Leuk Lymphoma
; 63(7): 1754-1757, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35253587